{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:45:52Z","timestamp":1747187152362,"version":"3.40.5"},"reference-count":44,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Kron et al (Mycoses, 64, 2021, 86) found cost savings for the use of the innovative pharmaceutical isavuconazole in the inpatient setting in Germany (Bismarck\u2010based healthcare system). Little is known about the reimbursement of innovative pharmaceuticals in the inpatient setting of Beveridge\u2010based healthcare systems.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this study was to evaluate the market access process and reimbursement of isavuconazole, exemplary for innovative pharmaceuticals, in England and Spain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients\/Methods<\/jats:title><jats:p>Market access processes of both countries were described. Focussing on typical patient clusters for isavuconazole treatment, reimbursement data regarding inpatients with (i) allogeneic haematopoietic stem cell transplantation or (ii) acute myeloid leukaemia was considered. Data were publicly available and of high topicality (England 2020\/2021, Spain 2018). Discounting and a currency conversion to Euro were applied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study showed that market access processes of both countries are broadly similar. Further, full reimbursement of isavuconazole as an innovative pharmaceutical may lead to reduction in resource utilisation. Without medication costs, isavuconazole can thus result in cost savings for both patient clusters due to a reduction in length of stay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Expenses for innovative pharmaceuticals may be balanced or even lead to cost savings due to a reduction in length of stay. The latter contributes to a greater patient benefit. For both healthcare system, the analyses highlighted drugs\u2019 cost\u2010effectiveness and assessing its added value into reimbursement decisions is highly relevant.<\/jats:p><\/jats:sec>","DOI":"10.1111\/myc.13336","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T16:15:50Z","timestamp":1623860150000},"page":"1213-1222","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reimbursement of innovative pharmaceuticals in English and Spanish hospitals\u2014The example of isavuconazole"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4669-690X","authenticated-orcid":false,"given":"Julia","family":"Jeck","sequence":"first","affiliation":[{"name":"VITIS Healthcare Group Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4232-6944","authenticated-orcid":false,"given":"Sebastian M.","family":"Wingen\u2010Heimann","sequence":"additional","affiliation":[{"name":"VITIS Healthcare Group Cologne Germany"},{"name":"Department I of Internal Medicine Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany"},{"name":"FOM University of Applied Sciences Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Thielscher","sequence":"additional","affiliation":[{"name":"FOM University of Applied Sciences Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kron","sequence":"additional","affiliation":[{"name":"VITIS Healthcare Group Cologne Germany"},{"name":"Department I of Internal Medicine Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany"},{"name":"Network Genomic Medicine University Hospital Cologne Cologne Germany"},{"name":"Faculty of Medicine and University Hospital Cologne Center for Integrated Oncology (CIO ABCD) University of Cologne Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Bonn","sequence":"additional","affiliation":[{"name":"VITIS Healthcare Group Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Jakobs","sequence":"additional","affiliation":[{"name":"VITIS Healthcare Group Cologne Germany"},{"name":"Department I of Internal Medicine Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany"},{"name":"Network Genomic Medicine University Hospital Cologne Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[{"name":"Pharmacy Department Hospital del Mar Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Enoch","sequence":"additional","affiliation":[{"name":"Clinical Microbiology &amp; Public Health Laboratory National Infection Service Public Health England Addenbrookes Hospital Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christianne","family":"Micallef","sequence":"additional","affiliation":[{"name":"Pharmacy &amp; Microbiology Departments Cambridge University Hospitals NHS Foundation Trust Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany"},{"name":"Faculty of Medicine and University Hospital Cologne Center for Integrated Oncology (CIO ABCD) University of Cologne Cologne Germany"},{"name":"Faculty of Medicine and University Hospital Cologne Clinical Trials Centre Cologne (ZKS K\u00f6ln) University of Cologne Cologne Germany"},{"name":"Faculty of Medicine and University Hospital Cologne Cologne Excellence Cluster on Cellular Stress Responses in Aging\u2010Associated Diseases (CECAD) University of Cologne Cologne Germany"},{"name":"Faculty of Medicine and University Hospital Cologne Excellence Center for Medical Mycology (ECMM) University of Cologne Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4907-7490","authenticated-orcid":false,"given":"Florian","family":"Kron","sequence":"additional","affiliation":[{"name":"VITIS Healthcare Group Cologne Germany"},{"name":"Department I of Internal Medicine Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany"},{"name":"FOM University of Applied Sciences Essen Germany"},{"name":"Faculty of Medicine and University Hospital Cologne Center for Integrated Oncology (CIO ABCD) University of Cologne Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.46548-0"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12257-018-0477-0"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof5010026"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.02929.x"},{"issue":"12","key":"e_1_2_8_6_1","first-page":"e405\u201021","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"9","author":"Cornely O","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.002"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-7-94"},{"key":"e_1_2_8_9_1","unstructured":"Health Expenditure Per Capita.Health at a Glance 2019: OECD Indicators;2019.https:\/\/www.oecd\u2010ilibrary.org\/sites\/876d99c3\u2010en\/index.html?itemId=\/content\/component\/876d99c3\u2010en. Accessed December 01 2020."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13192"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.suppl_6.3"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703738"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01096.x"},{"issue":"8","key":"e_1_2_8_14_1","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM\u20102004 study","volume":"91","author":"Pagano L","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.012054"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_2_8_17_1","unstructured":"General Methods Version \u2010 6.0 of 05.11.2020.2020;Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG).https:\/\/www.iqwig.de\/methoden\/allgemeine\u2010methoden_version\u20106\u20100.pdf?rev=180500. Accessed March 24 2021."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00301.x"},{"key":"e_1_2_8_19_1","unstructured":"Annex DtA: The national tariff workbook 2020\/21.2020;National Health Service Improvement.https:\/\/www.england.nhs.uk\/publication\/national\u2010tariff\u2010payment\u2010system\u2010documents\u2010annexes\u2010and\u2010supporting\u2010documents\/. Accessed April 15 2021."},{"key":"e_1_2_8_20_1","unstructured":"A guide to the market forces factor \u2010 A joint publication by NHS England and NHS Improvement.2019;National Health Service Improvement \/ National Health Service England.https:\/\/improvement.nhs.uk\/documents\/4995\/1920_Guide__to_MFF.pdf. Accessed March 24 2021."},{"key":"e_1_2_8_21_1","unstructured":"W\u00c4HRUNGSRECHNER: BRITISCHE PFUND \u2010 EURO (GBP IN EUR).https:\/\/www.finanzen.net\/waehrungsrechner\/britische\u2010pfund_euro. Accessed December 1 2020."},{"key":"e_1_2_8_22_1","unstructured":"Blueteq established as the system for High Cost Drugs Management Process in NHS England's Commissioning Intentions 2016\/2017!.Blueteq Ltd.http:\/\/www.blueteq.com\/latestnews\/ArticleID\/2\/Blueteq\u2010established\u2010as\u2010the\u2010system\u2010for\u2010High\u2010Cost\u2010Drugs\u2010Management\u2010Process\u2010in\u2010NHS\u2010Englands\u2010Commissioning\u2010Intentions\u20102016\u20102017. Accessed December 01 2020."},{"key":"e_1_2_8_23_1","unstructured":"Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. CMBD. Norma Estatal.2018;Ministerio de Sanidad Consumo y Bienestar Social.https:\/\/www.mscbs.gob.es\/estadEstudios\/estadisticas\/cmbd.htm. Accessed December 01 2020."},{"key":"e_1_2_8_24_1","unstructured":"About CCGs.National Health Service Clinical Commissioners (NHSCC).https:\/\/www.nhscc.org\/ccgs\/. Accessed December 01 2020."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0144-z"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.09.1337"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1638789"},{"key":"e_1_2_8_28_1","unstructured":"The 2019 Voluntary Scheme for Branded Medicines Pricing and Access \u2010 Chapters and Glossary.2018;Department of Health & Social Care \/ Association of the British Pharmaceutical Industry.https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/761834\/voluntary\u2010scheme\u2010for\u2010branded\u2010medicines\u2010pricing\u2010and\u2010access\u2010chapters\u2010and\u2010glossary.pdf. Accessed March 23 2021."},{"key":"e_1_2_8_29_1","unstructured":"Specialised Services.National Health Service England.https:\/\/www.england.nhs.uk\/commissioning\/spec\u2010services\/. Accessed January 18 2021."},{"key":"e_1_2_8_30_1","unstructured":"High cost drugs.2012;GOV.UK.https:\/\/www.gov.uk\/government\/news\/high\u2010cost\u2010drugs\u2010\u20102. Accessed March 23 2021."},{"key":"e_1_2_8_31_1","unstructured":"Contracts and payment guidance October 2020 \u2013 March 2021.2020;National Health Service.https:\/\/www.england.nhs.uk\/wp\u2010content\/uploads\/2020\/09\/C0768\u2010finance\u2010guidance\u2010with\u2010annex\u20103\u2010added\u201023\u2010september\u20102020\u2010.pdfAccessed March 24 2021."},{"key":"e_1_2_8_32_1","unstructured":"Single Technology Appraisal \u2010 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508] \/ Committee Papers.2019;National Institute for Health and Care Excellence.https:\/\/www.nice.org.uk\/guidance\/ta640\/evidence\/appraisal\u2010consultation\u2010committee\u2010papers\u2010pdf\u20108828294941. Accessed March 24 2021."},{"key":"e_1_2_8_33_1","unstructured":"FICHA TECNICA CRESEMBA 100mg capsulas duras.Agencia espanola de medicamentos y productos sanitarios \/ Centro de informaci\u00f3n de medicamentos.https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1151036002\/FT_1151036002.html. Accessed March 24 2021."},{"key":"e_1_2_8_34_1","unstructured":"FICHA TECNICA CRESEMBA 200mg polvo para concentrado para solucion para perfusion.Agencia espanola de medicamentos y productos sanitarios \/ Centro de informaci\u00f3n de medicamentos.https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1151036001\/FT_1151036001.html. Accessed March 24 2021."},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.06.012"},{"key":"e_1_2_8_36_1","unstructured":"Funciones Direcci\u00f3n General de Cartera B\u00e1sica de Servicios del Sistema Nacional de Salud y Farmacia. Ministerio de Sanidad Consumo y Bienestar Social.https:\/\/www.mscbs.gob.es\/organizacion\/ministerio\/organizacion\/sgralsanidad\/dgcbssnsyfF.htm. Accessed March 23 2021."},{"key":"e_1_2_8_37_1","unstructured":"Real Decreto\u2010ley 8\/2010 de 20 de mayo por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico; Cap\u00edtulo V Art\u00edculo 8.2010; BOE\u2010A\u20102010\u20108228;Boletin Oficial del Estado \u2010 Legislacion Consolidada.https:\/\/www.boe.es\/buscar\/pdf\/2010\/BOE\u2010A\u20102010\u20108228\u2010consolidado.pdf. Accessed March 24 2020."},{"key":"e_1_2_8_38_1","unstructured":"Real Decreto\u2010ley 8\/2010 de 20 de mayo por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico; Cap\u00edtulo V Art\u00edculo 9.2010; BOE\u2010A\u20102010\u20108228;Boletin Oficial del Estado \u2010 Legislacion Consolidada.https:\/\/www.boe.es\/buscar\/pdf\/2010\/BOE\u2010A\u20102010\u20108228\u2010consolidado.pdf. Accessed March 24 2021."},{"key":"e_1_2_8_39_1","unstructured":"Real Decreto\u2010ley 8\/2010 de 20 de mayo por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico; Cap\u00edtulo V Art\u00edculo 10.2010; BOE\u2010A\u20102010\u20108228;Boletin Oficial del Estado \u2010 Legislacion Consolidada.https:\/\/www.boe.es\/buscar\/pdf\/2010\/BOE\u2010A\u20102010\u20108228\u2010consolidado.pdf. Accessed March 24 2021."},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.7175\/747.ch6"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-012-1473-8"},{"key":"e_1_2_8_42_1","unstructured":"Expert Panel on effective ways of investing in Health (EXPH).Innovative payment models for high\u2010cost innovative medicines.Health;2018.https:\/\/ec.europa.eu\/health\/sites\/health\/files\/expert_panel\/docs\/opinion_innovative_medicines_en.pdf. Accessed March 24 2021."},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-12169-7_20"},{"key":"e_1_2_8_44_1","unstructured":"HurstL MahtaniK PluddemannA et al.Defining value\u2010based healthcare in the NHS: The CEBM Report.Centre for Evidence\u2010Based Medicine.2019."},{"key":"e_1_2_8_45_1","unstructured":"Current healthcare expenditure relative to GDP 2017.2020; Eurostat \u2010 Statistics Explained;2017.https:\/\/ec.europa.eu\/eurostat\/statistics\u2010explained\/index.php\/Healthcare_expenditure_statisticsAccessed December 01 2020."}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.13336","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/myc.13336","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.13336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:39:32Z","timestamp":1692841172000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.13336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/myc.13336"],"URL":"https:\/\/doi.org\/10.1111\/myc.13336","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"type":"print","value":"0933-7407"},{"type":"electronic","value":"1439-0507"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"2021-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}